To provide world-class joint treatments across North India...
![[From L-R]: Feng Dong, Vice President, Medtronic Asia Region-Led Market; H.E. Sarah McGrath, Ambassador at Embassy of Ireland in Singapore; Jacqueline Poh, Managing Director, EDB; Majid Kaddoumi, Senior Vice President and President, Medtronic Europe, Midd](/uploads/articles/medtronic_se_asia-23438.png)
To accelerate adoption of Robotics and AI across Southeast Asia through training and education...
Enables future innovation opportunities for closed-loop hemodynamic monitoring...
For global distribution of Rockwell’s hemodialysis products ...
To enable rapid delivery of treatment to patients...
Aim to bridge healthcare divides worldwide...
Clinical trial agreement preludes planned international launch for the mBôs TKA System...
Kochi Academy is strategically placed to meet the educational needs of healthcare professionals in Southern India...
Advancing personalised medicine has become a key goal for many pharma firms, evident from the rising number of such therapies under clinical development. In 2022 alone, 12 new personalised medicines were approved, marking these treatments as accounting for at least a quarter of new drug approvals over the past eight years. This contrasts sharply with a decade ago when personalised medicines constituted less than 10 per cent of new approvals annually, according to The Personalised Medicine Coalit...
To reduce infections, healthcare costs and improve patient outcomes...
